 PRINCETON, N.J., March 02, 2021 GLOBE NEWSWIRE -- Oyster Point Pharma, Inc. Nasdaq: OYST, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the U.S. Food and Drug Administration FDA has accepted its New Drug Application NDA for OC-01 varenicline nasal spray for the treatment of signs and symptoms of dry eye disease. The Prescription Drug User Fee Act PDUFA target action date for OC-01 varenicline nasal spray is October 17, 2021. At present, FDA has stated that it does not intend to hold an advisory committee meeting to discuss this application. 